Loading…
Loading…
EQUITY / NASDAQ · XNCM
Indaptus Therapeutics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗2.38 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 2.38 USD · Volume 568,163
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -1,808,866 USD | -4,456,763 USD | — |
| Net income | -1,794,863 USD | -5,228,919 USD | — |
| Cash and cash equivalents | 7,553,820 USD | — | — |
| Total liabilities | 615,426 USD | — | — |
| Total equity | 11,372,530 USD | -1,673,356 USD | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 7,553,820 USD | — | — | 8,507,628 USD | 8,507,628 USD | 5,825,639 USD | — | — |
| Net incomeIncome statement | -1,794,863 USD | -4,335,933 USD | -2,541,070 USD | — | -20,848,916 USD | -2,975,117 USD | -12,736,466 USD | -5,228,919 USD |
| Operating profitIncome statement | -1,808,866 USD | -3,968,454 USD | — | — | -19,833,513 USD | -2,648,487 USD | -11,677,809 USD | -4,456,763 USD |
| Total assetsBalance sheet | 11,987,956 USD | — | — | 9,310,168 USD | 9,310,168 USD | 6,840,052 USD | — | — |
| Total equityBalance sheet | 11,372,530 USD | — | 1,247,857 USD | 3,151,593 USD | 3,151,593 USD | 4,605,727 USD | — | -1,673,356 USD |
| Total liabilitiesBalance sheet | 615,426 USD | — | — | 6,158,575 USD | — | — | — | — |
| Financing cash flowCash flow statement | — | 11,983,819 USD | — | — | 17,544,131 USD | — | 11,671,629 USD | — |
| Investing cash flowCash flow statement | — | -4,000,000 USD | — | — | — | — | — | — |
| Operating cash flowCash flow statement | — | -8,937,627 USD | — | — | -14,823,256 USD | — | -11,632,743 USD | — |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/17/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.